Home

The third Critical Assessment of Computational Hit-finding Experiments (CACHE) challenged computational teams to identify chemically novel ligands targeting the macrodomain 1 of SARS-CoV-2 Nsp3, a promising coronavirus drug target. Twenty-three groups deployed diverse design strategies to collectively select 1739 ligand candidates. While over 85% of the designed molecules were chemically novel, the best experimentally confirmed hits were structurally similar to previously published compounds. Confirming a trend observed in CACHE #1 and #2, two of the best-performing workflows used compounds selected by physics-based computational screening methods to train machine learning models able to rapidly screen large chemical libraries, while four others used exclusively physics-based approaches. Three pharmacophore searches and one fragment growing strategy were also part of the seven winning workflows. While active molecules discovered by CACHE #3 participants largely mimicked the adenine ring of the endogenous substrate, ADP-ribose, preserving the canonical chemotype commonly observed in previously reported Nsp3-Mac1 ligands, they still provide novel structure–activity relationship insights that may inform the development of future antivirals. Collectively, these results show that multiple molecular design strategies can efficiently converge on similar potent molecules.

The glomerular filtration barrier poses a significant challenge for circulating proteins, with molecules below ~60–70 kDa facing rapid renal clearance. Endogenous proteins have evolved sophisticated evasion mechanisms including oligomerization, carrier binding, electrostatic repulsion, and FcRn-mediated recycling. Understanding these natural strategies provides blueprints for engineering therapeutic proteins with improved pharmacokinetics. This review examines how endogenous proteins resist filtration, evaluates their application in protein engineering, and discusses clinical translation including established technologies (PEGylation, Fc-fusion) and emerging strategies (albumin-binding domains, glycoengineering). We address critical challenges of balancing half-life extension with tissue penetration, biological activity, and immunogenicity—essential considerations for the rational design of next-generation therapeutics with optimized dosing and enhanced efficacy.

Artificial intelligence (AI)-based prostate cancer detection through whole slide images (WSIs) offers promising potential to address the global pathologist shortage while improving clinical consistency. Digital slides and improving image analysis methods encourage the creation of tools to aid in WSI classification. Despite promising advances, these tools are still limited by available training data. Current publicly available datasets, such as Kaggle's PANDA Challenge, while large in scale, rely on slide-level labels that may introduce noise and limit model reliability. Others contain detailed annotations, but are smaller in size due to manual processing efforts. In this work, we introduce PANDA-PLUS, a 546-image dataset derived from PANDA images with improved pixel-level annotations, as well as an accompanying annotation pipeline that reduces pathologists' time commitment. We present a detailed comparative analysis between PANDA-PLUS and PANDA using Gleason score and ISUP grade, supported by agreement values, κ, and PABAK under multiple weighting schemes. The results demonstrate consistently lower grading in PANDA-PLUS, with disagreement patterns especially pronounced at higher grades. We also demonstrate through single rater grading of various annotation granularities how slide- and patch-level labels may distort grading proportions and alter image scores. PANDA-PLUS not only improves annotation granularity and reduces label noise but also exposes potential grading errors in the original PANDA dataset. We present PANDA-PLUS's annotations as an improved alternative to the PANDA labels and conclude that it represents a step forward in the development of higher-quality public datasets for clinical AI applications in prostate cancer pathology.